Clinical Trials
18 trialsNCT07629960 2026-06-05
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Blueprint Medicines Corporation
Phase 1/2 Recruiting
NCT02465060 2026-06-03
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06051695 2026-05-26
EVEREST-2
A2 Biotherapeutics Inc.
Phase 1/2 Recruiting
NCT06337552 2026-05-26
High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial)
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Active not recruiting
NCT06607185 2026-05-26
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
NCT06704724 2026-05-22
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
Phase 1 Terminated
NCT07596732 2026-05-19
SUNRISE
AdventHealth Translational Research Institute
Phase NA Not yet recruiting
NCT06904365 2026-05-18
OvAR-Y
Washington University School of Medicine
Active not recruiting
NCT05462717 2026-05-15
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
Phase 1 Active not recruiting
NCT05715255 2026-05-14
Adaptive Symptom Self-Management Immunotherapy Study
University of Arizona
Phase NA Recruiting
NCT06673329 2026-05-13
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
Phase 1 Recruiting
NCT07458347 2026-05-12
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Kestrel Therapeutics, Inc.
Phase 1 Recruiting
NCT06239194 2026-05-06
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
Phase 1/2 Recruiting
NCT02012699 2026-05-05
iCaRe2
University of Nebraska
Recruiting
NCT05983133 2026-05-05
A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
Seagen Inc.
Phase 1 Terminated
NCT05297734 2026-04-30
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Stanford University
Phase NA Recruiting
NCT06128551 2026-04-23
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Revolution Medicines, Inc.
Phase 1/2 Recruiting
NCT06447662 2026-04-20
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Pfizer
Phase 1 Recruiting